EULAR 2024

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

Difference in axial involvement in axSpA and axPsA

JAK inhibitors in GCA - a good opportunity?

Tapering or even stopping TNF inhibitors in pts. with…

Handling cardiovascular risks in RA

Factors associated with spinal progression in axSpA

Treat-to-target approach to induce sustained clinical…

Minimal spinal radiographic progression with…

Avoiding overdiagnosis in axSpA

Neuroinflammation as possible cause of intestinal…

Treat-to-target in axSpA - a long way to go!

Sooner or later - when therapy with biologics?

Uterine inflammation in the pathogenesis in axSpA

Treat-to-target bei der axSpA - a long way to go!

Approccio treat-to-target per indurre una remissione…

Vermeidung von Überdiagnose bei axSpA

Minimale Röntgenprogression der Wirbelsäule unter…

Früher oder später - wann Therapie mit Biologika?

Ruolo dell’infiammazione uterina nella patogenesi…

Ruolo della neuroinfiammazione della patogensi…

Tyk2 inhibition in PsA - a new opportunity?

Difference in axial involvement in axSpA and axPsA

Subclinical PsA - where is the border?

A new injection for knee osteoarthritis

A mouse model for PsA and PsO!

The difficult cases in PsA

Sonelokimab, a new molecule for IL-17A & IL-17F…

Managing comorbidities in PsA

Post-hoc analysis on severe disease activity in PsA

The JAK family is growing. Another Tyk2 inhibitor: safe…

A lot of steroids always help - no matter the…

12-weeks results from the PRO-SPIRIT study

Treatment strategy in early PsA - TnF inhibitors or…

Early prediction by FAPI-PET in PsA

Small molecules with a better enthesitis efficacy - new…

Cardiovascular outcome in PsA - TnF vs. IL-17…

Risultati a 12 settimane dello studio di Real World…

Risque cardiovasculaire et rhumatisme psoriasique :…

Rhumatisme psoriasique débutant : anti TNF ou pas?

Frühe Prädiktion durch FAPI-PET bei PsA

Sonelokimab, ein neues Molekül zur IL-17A- &…

Valutazione della risposta a due anni di trattamento…

Quel traitement pour prévenir l’évolution du psoriasis…

Kleine Moleküle mit besserer Enthesitiswirkung - neue…

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor:…

Deeper B-cell depletion

JAK inhibitors in GCA - a good opportunity?

Tapering or even stopping TNF inhibitors in pts. with…

Debate on regulatory safety measures for JAKies based…

Real-world data on safety of etanercept biosimilar

Potential new treatment class in RA

Tapering of TNF Inhibitors in RA Patients with…

Abatacept vs adalimumab in dual seropositive RA…

A model to predict progression from palindromic…

New JAK inhibitor tested in a Phase III trial in China

No new safety signals from the JAK-POT study

Statins in RA - who benefits?

Debate on therapeutic drug monitoring

Good news in RA

Anti-citrullinated protein antibody (ACPA) does not…

Un modelo para predecir la progresión del reumatismo…

Keine neuen Safety-Signale aus der JAK-POT Studie

Abatacept vs adalimumab en pacientes con AR doble…

ARCTIC REWIND – dosereduksjon og seponering anbefales…

Debatt om bruk av therapeutic drug monitoring (TDM,…

Reducción y suspensión de los inhibidores del TNF en…

Debatt om regulatoriske krav om sikkerhet ved bruk av…

En ny JAK hemmer undersøkt i en fase III studie I Kina

The role of rheumatoid factor from early to late

AI in rheumatology

How to treat Lupus: What's on the horizon?